Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL680561 | 0.89 | MMP13 (0.65) | HDAC1HDAC6ALDH1A1GAASCN9A | |
| SCHEMBL29765489 | 0.82 | HDAC1 (0.61) | HDAC1HDAC6ALDH1A1GAANPC1 | |
| SCHEMBL22097521 | 0.82 | SCN9A (0.54) | HDAC1HDAC6SCN9AP4HTMPTPN1 | |
| SCHEMBL7987812 | 0.82 | SCN9A (0.55) | GAASCN9AP4HTMPTGS2MEN1 | |
| SCHEMBL7118965 | 0.82 | ALDH1A1 (0.58) | HDAC1HDAC6ALDH1A1SCN9AP4HTM | |
| SCHEMBL3374779 | 0.82 | SCN9A (0.54) | ALDH1A1SCN9ANPC1RAB9AP4HTM | |
| SCHEMBL9913954 | 0.82 | KMT2A (0.54) | ALDH1A1GAASCN9ANPC1RAB9A | |
| SCHEMBL7990845 | 0.82 | FLT1 (0.65) | ALDH1A1SCN9AP4HTMPTGS2LMNA | |
| SCHEMBL1647742 | 0.82 | LMNA (0.54) | ALDH1A1SCN9ANPC1RAB9AP4HTM | |
| SCHEMBL364110 | 0.81 | HDAC3 (0.58) | HDAC1HDAC6ALDH1A1GAASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9714240-B2 | Vinyl autotaxin inhibitor compounds | PHARMAKEA, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| WO-2017051355-A1 | COMPOUNDS WITH HIV MATURATION INHIBITORY ACTIVITY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017017607-A1 | BETUIN DERIVATIVES FOR PREVENTING OR TREATING HIV INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-02-02 | — | — | WO | disclosed |
| US-20160222000-A1 | VINYL AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-08-04 | — | — | US | disclosed |
| US-9096500-B2 | Acyl sulfonamide compounds | PFIZER LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| US-9096500-B2 | Acyl sulfonamide compounds | PFIZER LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| US-9096500-B2 | Acyl sulfonamide compounds | PFIZER LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| EP-1882684-B1 | PYRROLIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-12-10 | — | — | EP | disclosed |
| EP-2593428-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2014-11-19 | — | — | EP | disclosed |
| EP-2593428-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2014-11-19 | — | — | EP | disclosed |
| US-8134013-B2 | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| WO-2012007868-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| WO-2011043359-A1 | PHARMACEUTICAL PRODUCT CONTAINING AROMATIC HETEROCYCLIC COMPOUND | 協和発酵キリン株式会社 (JP) | 2011-04-14 | — | — | WO | disclosed |
| US-7585886-B2 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-7585886-B2 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARAMA INC. (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARAMA INC. (JP) | 2009-03-05 | — | — | US | disclosed |
| US-6331628-B1 | REACTING A SUBSTITUTED HALOBENZENE WITH POTASSIUM, SODIUM AND/OR ZINC CYANIDE IN THE PRESENCE OF A METALLIC CATALYST | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2001-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | CASR, CYP2R1, PTH1R | HDAC1 1710/4885HDAC6 3294/4885ALDH1A1 2179/4885 |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, PTAFR, MPL | HDAC1 1145/4885HDAC6 2255/4885ALDH1A1 2047/4885 |
| US-20160222000-A1 | VINYL AUTOTAXIN INHIBITOR COMPOUNDS | ENPP2, SERPINB1, SERPINB10 | HDAC1 1392/4885HDAC6 404/4885ALDH1A1 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.